Nona Biosciences reveals a partnership with Evive Biotech aimed at speeding up antibody discovery.

Cambridge: On December 10, 2023, Nona Biosciences, a leading global innovator in technology and solutions for antibody discovery and development, entered into a collaboration agreement with Evive Biotech, a global biopharmaceutical company dedicated to developing an array of innovative biological therapies for global patient populations. This collaboration centers around the utilization of Nona Biosciences' Harbour Mice® antibody technology platform. By leveraging the respective strengths of Nona Biosciences and Evive Biotech, the partnership aims to expedite the antibody discovery and drug development processes, ultimately bringing benefits to patients more rapidly.

The Harbour Mice® represents an exclusive antibody technology platform employing transgenic mice to produce fully human monoclonal antibodies, available in both the traditional two heavy and two light chain (H2L2) format and a heavy chain only (HCAb) format. This platform carries substantial promise for advancing therapeutic antibody development and expediting the drug discovery and development processes.

Jingsong Wang, MD, PhD, Chairman of Nona Biosciences said, "Nona Biosciences is committed to bringing antibody discovery and research solutions to our partners better and faster. With the capabilities of Harbour Mice®, we look forward to empowering our partners in antibody drug discovery and development, and helping more patients benefit from cutting-edge technologies and therapies."

Simon Li, MD, PhD, CEO & CMO of Evive Biotech said, “There is tremendous potential in antibody-based therapy, and I am very excited about this collaboration. Evive Biotech's mission is to develop innovative biologic therapies for patients worldwide. We eagerly anticipate collaborating with Nona Biosciences to accelerate the discovery of innovative antibody therapies to benefit patients across the globe."

Nona Biosciences is a worldwide biotechnology firm dedicated to pioneering technological innovation. It delivers a comprehensive solution from the conceptual stage to the Investigational New Drug (IND) milestone, encompassing target validation, antibody discovery, and preclinical research. The all-encompassing antibody discovery services span antigen preparation, animal immunization, rigorous antibody screening, lead generation, engineering, developability assessment, and pharmacological evaluation. These services capitalize on the strengths of Harbour Mice® technology and an adept therapeutic antibody discovery team.

Harbour Mice® produce fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and a heavy chain only (HCAb) format. Through the strategic integration of Harbour Mice® with advanced antibody screening platforms, Nona Biosciences is dedicated to spearheading worldwide innovations in the development of groundbreaking next-generation drugs.

Evive Biotech utilizes its exclusive technology platforms to progress a range of inventive drug candidates targeting oncology, inflammatory, and metabolic diseases. Pioneering as the first biopharmaceutical company to establish a platform for introducing innovative therapies from China to the global market, Evive employs a comprehensive strategy in drug development. This strategy integrates outstanding research and commercialization capabilities with their top-tier in-house regulatory expertise and extensive international management experience.

According to TechSci Research, the partnership between Nona Biosciences and Evive Biotech is positioned to yield substantial advantages for the healthcare sector. This collaboration has the capacity to optimize and improve the process of developing therapeutic antibodies, thereby playing a crucial role in the innovation and creation of groundbreaking pharmaceuticals. The combination of Nona Biosciences' sophisticated antibody discovery services including antigen preparation, animal immunization, antibody screening, lead generation, engineering, developability assessment, and pharmacological evaluation with Evive Biotech's proficiency and platform focused on innovative drug candidates for oncology, inflammatory, and metabolic diseases, establishes a synergistic collaboration. This joint initiative is poised to accelerate the development of novel and efficacious therapies. Their main objective is to unveil revolutionary next-generation drugs addressing unmet medical needs in critical domains like oncology, inflammatory diseases, and metabolic disorders. The favorable results anticipated from this partnership could profoundly influence patient care by furnishing healthcare professionals with advanced tools and solutions, thereby enhancing treatment outcomes and patient well-being.